Objectives. To investigate the influence of HLA-DRB1 alleles encoding the QK/RRAA shared epitope (SE) on radiological outcome in rheumatoid arthritis (RA), and to determine whether it is modulated by alleles carrying the putative rheumatoid arthritis-protective (RAP) sequence DERAA.
Rheumatoid arthritis (RA) is a heterogeneous disease RA [2] . These DRB1 alleles all share a highly conserved in which patients show considerable variation in disease amino acid sequence (QKRAA, QRRAA or RRRAA) progression and clinical outcome. The aetiology of RA in the third hypervariable region (HVR3) of the molis still unclear, and both environmental and genetic ecule, which forms part of the peptide binding pocket factors are believed to contribute to development of in the DR heterodimer [3] . This conserved sequence is disease [1] . Genes that lie within the HLA class II region commonly referred to as the RA 'shared epitope' (SE ) have been studied extensively, and several HLA-DRB1 [4] , but although this association has been known for alleles (DRB1*0401, *0404, *0405, *0408, *0101, *0102, over 10 yr, the role of DRB1 molecules in RA aetiology *1001, *1402) have been shown to be associated with remains unclear [5] .
There has been considerable debate as to whether the HLA-DRB1 alleles influence susceptibility or disease diagnosed patients in the community is similar to that Patients and methods in controls [7] , while some prospective hospital-based
The association between HLA-DRB1 types and radiolostudies have shown an association between HLA-DR4 gical severity was studied in 315 unrelated northern and more severe disease [8] . In contrast, a recent comEuropean Caucasians resident in north Staffordshire munity-based study suggested that DR4, and in parand suffering from RA ( Table 1) . They were recruited ticular DR1/DR4 heterozygosity, were related to suscepconsecutively between 1986 and 1996 in a clinic estabtibility to RA rather than disease severity, and only in lished to examine the effects of slow-acting antiseropositive patients [9] . Such conflicting data may rheumatic drugs. Chloroquine/hydroxychloroquine and reflect the milder disease seen in community settings. In dapsone were generally used first, followed by sulphasalhospital-based studies of RA, data suggest that not all azine, gold and -penicillamine. Therapy was adminisalleles carrying the SE provide equal risk of developing tered as clinically indicated. Details of some these severe disease, with particular combinations of these patients have been described in previous studies [17, alleles (e.g. DRB1*0401/0404) being associated with 18]. The ARA criteria of 1958 were recorded at the worse disease [10, 11] .
initial presentation and used as the basic definition of Previous studies have suggested that certain HLA-DR the group. The 1987 ARA criteria were documented phenotypes are protective, based on their reduced retrospectively from data in the case notes. Since we frequencies in RA cases compared with controls.
were primarily interested in the association with longThe frequencies of DR2 (DRB1*15), DR3, DR5
term radiological outcome, we only included patients (DRB1*11/*12) and DR7 haplotypes have all been with a disease duration of 5 yr or more. These had all shown to be decreased in epidemiological studies [2, 12, been reviewed annually for at least 5 yr and their disease 13]. However, the effect of individual DRB1 alleles had been extensively characterized. This enabled greater lacking the SE on disease severity is not clear. Recently, certainty of disease classification and assessment of it has been suggested that the association of RA with disease progression and severity. Radiographic outcome, some DRB1 alleles can be explained by their linkage recorded at final review, was obtained by scoring X-rays with HLA-DQ alleles displaying affinity for similar of the hands and feet using the method of Larsen et al. 'arthritogenic' peptides [14] . According to this model, [19] . Posterior-anterior radiographs of both hands and certain HLA-DQ alleles predispose to severe RA, but a anterior-posterior radiographs of both feet were taken, self-peptide sequence (containing the DERAA motif ) and examined without knowledge of HLA-DRB1 genofrom the third hypervariable region of some DRB1 type, by three experienced observers. All observers were alleles (DRB1*0103, *0402, *1102, *1103, *1301 and trained in the use of the Larsen score. Inter-and intra-*1302) can protect from disease if presented by DQ observer reliability was assessed as described previously molecules. Studies in HLA-DQ8 transgenic mice showed [18] , and showed no systematic bias between readings. Joint changes were classified by comparison with a correlation between the DQ8-restricted T-cell response standard reference films and were graded 0-5, where to DRB1 HVR3 peptides and non-association of the 0 = normal, 1 = slight change (including soft-tissue corresponding DRB1 alleles with RA in humans [15] .
swelling, osteoporosis or joint space narrowing), Further analysis of the immunogenicity of the 2 = definite early abnormality, 3 = medium destruc-DRB1*0402 HVR3 peptide in DQ8-transgenic mice tive changes, 4 = severe destructive changes and demonstrated that the DERAA motif determined both 5 = mutilating change. Operated joints were graded as DQ8 binding and T-cell receptor ( TCR) recognition scale 5. The final Larsen score was defined for each [16 ] . It was proposed that polymorphisms at positions examination as the sum of the grades of the affected 70 and 71 of the DRB1 molecules are likely to distinguish joints. The maximum possible score was 210. RA-predisposed from RA-protected individuals by inducing differences in their T-cell repertoire during thymic HLA-DRB1 typing education.
HLA-DRB1 typing was performed by polymerase chain The association of DRB1 HVR3 sequences with RA reaction-single-strand conformation polymorphism severity measures and their predictive value for clinical outcome may be of prognostic value. In order to test Regression coefficients with standard errors (..)and P values (before and after correction for multiple testing) are shown for multiple regression analyses carried out to investigate the association between Larsen scores (dependent variable) and each phenotype (e.g. DRB1*01 vs non-DRB1*01). All analyses were corrected for age, sex and disease duration. Patients with DRB1*08, *09 and *10 were not considered because of the small sample size.
ND, not done. NS, non-significant (P > 0.05).
(PCR-SSCP) using a panel of sequence-specific oligonuof radiological damage in patients according to their DRB1 type. If any particular DRB1 allele was 'protectcleotide probes selected from the set recommended by the 12th International Histocompatibility Workshop ive' in the presence of an SE allele, then this might be expected to be reflected by a lower Larsen score in [20] . Probes were selected to define allele group specificity, and those carrying the RA 'SE' or RA patients with the 'protective' phenotype. Our data demonstrated that DRB1*04-positive patients (n = 211) had 'protective' epitope. All probes were 5∞ end-labelled with biotin and bound probe was detected by enhanced the highest Larsen score ( Table 2) , this being significantly different to that in patients (n = 104) lacking the chemiluminescence (Amersham, UK ). HLA-DRB1*04 subtyping was performed by PCR-SSCP [21] or using *04 allele (98.2 vs 86.0; P = 0.006). This was still significant after correction for multiple testing DRB1*04-specific LiPA strips (Innogenetics, Belgium).
(P = 0.042). Overall, the difference between phenotypes Statistical analysis was not large. The lowest Larsen scores were found in patients carrying DRB1*03 (85.0) or DRB1*13/*14 The associations between individual HLA-DRB1 phenotypes/genotypes and Larsen score were assessed using alleles (86.2), but these were not significantly different from patients negative for these phenotypes, after correcmultiple regression analysis which included the effect of the independent variables age, gender and disease duration for multiple testing. Patients with DRB1*08, *09 and *10 were not considered because of the low numbers tion. Where appropriate, correction for multiple testing was carried out using Holm's procedure [22, 23] .
involved. Interaction between SE and RA-protective (RAP) alleles was tested using multiple regression analysis with Larsen
Influence of the shared epitope on radiological outcome score as the dependent variable. The independent
We investigated whether the presence of an SE allele (explanatory) variables consisted of the interaction was having a significant effect on Larsen scores for each term RAP/SE as well as the individual main effects HLA-DRB1 phenotype. Apart from DRB1*01-and RAP+/− and SE+/−. Age, gender and disease dura-DRB1*04-positive patients, most DRB1 phenotypes tion were also included with the independent variables divided into groups with or without an accompanying to correct for any influence of these confounders. All SE allele revealed a trend towards lower Larsen scores analyses were carried out using the Number Cruncher in the SE − groups. We have shown this only for Statistical Package for Windows (NCSS Version 6.0.4). DRB1*13/*14 ( Table 2) , the one phenotype to show a P values of <0.05 were considered significant. statistically significant difference (P = 0.04) between SE − and SE+ groups. However, this should be treated with caution since correction for multiple testing causes Results loss of significance.
Association of HLA-DRB1 phenotype with radiological
Overall, patients positive for the SE had significantly outcome higher Larsen scores than SE-negative patients ( Table 3) . This difference could be accounted for mainly We initially stratified patients by HLA-DRB1 phenotype to examine whether it was possible to rank the amount by the lower Larsen scores of cases with DRB1*03, Regression coefficients with standard errors (..) and P values (before and after correction for multiple testing) are shown for multiple regression analyses carried out to investigate the association between Larsen scores (dependent variable) and each phenotype/genotype compared with SE−/−. All analyses were corrected for age, sex and disease duration. Patients with some SE homozygous genotypes were not considered because of the small sample size.
DRB1*11/*12 or DRB1*13/*14 in the SE− group. In the DERAA sequence, and further subdivided them into groups positive or negative for the QK/RRAA SE the SE+ group, there was no difference in radiological severity between individuals carrying one or two SE ( Table 4 ). The lowest Larsen score (65.6) was found in those cases carrying the DERAA sequence without an alleles. In patients homozygous for the SE, the highest Larsen score (99.9) was found in individuals with accompanying SE allele (RAP+/SE−), and this was significant (after correction for multiple testing) when DRB1*0401/0401. This was the only SE homozygote combination which demonstrated a statistically differcompared with RAP−/SE− (88.2; P = 0.05), RAP+/SE+ patients (105.6; P = 0.04) and ent Larsen score to that in SE − /SE − individuals ( Table 3) , although this was lost after adjustment for RAP−/SE+ (95.8; P = 0.009). There was no evidence to suggest that the RAP sequence was modulating the multiple testing. Compound genotypes for the SE (DRB1*0401/*0101, *0401/*0404 or *0408) were not effect of the SE since radiological outcome in SE+ patients was not significantly different between RAP+ significantly different to DRB1*0401/*0401 or *101/*0101 homozygote combinations, although comparisons and RAP− patients. Thus, in the presence of the SE+, the RAP+ alleles have no effect, i.e. there is no interbetween some combinations were limited by small patient numbers. action between them. A lack of interaction (P = 0.12) between the SE and RAP was confirmed by multiple Influence of the RA protective epitope on radiological regression analysis (Table 5 ) which included the interoutcome action term between SE and RAP as well as the corresponding main effects (SE+/− and RAP+/− The effect of DRB1*13 was of particular interest because the *1301 and *1302 alleles encode the so-called RAP separately). sequence DERAA at positions 70-74 of their HVR3. This sequence is also encoded by the *0103, *0402, nodules, vasculitis, etc.), rather than the continuous disease duration by including these covariates with the independent data used in our study (Larsen score). The use of variables. The F value for the model is 13.83 (P < 0.0001).
continuous data may account for the lack of an SE dose effect in our study since it takes into account the whole Discussion range of radiological severity in RA. Selection of patients may also lead to some disparity. For example, in a study In this study, we have examined the relationship between radiological outcome and HLA-DRB1 alleles in a large by Weyand et al.
[13], 46% of patients carried a double dose of the SE, with only a very small number (4%) group of well-characterized patients with long-standing RA. We have confirmed previous findings that patients being SE−/−. In our particular study, 34% of patients were SE+/+, while 20% were SE−/−. with DRB1 alleles carrying the QK/RRAA SE show more severe radiological change than patients lacking It is noteworthy that in our particular population the mean difference in Larsen score between the different the SE [24] . Although the highest Larsen scores were found in DRB1*04-positive patients, they were not genetic groups was quite small. Even putatively highrisk (SE+/+) patients had a Larsen score only~16% significantly higher than those in patients positive for DRB1*01, *15, *11, *12 and *09. This may be explained higher than 'low-risk' (SE−/−) patients. Although statistically significant, this may not be very different clinicby many of these patients carrying a DRB1*04 allele on their other HLA haplotype. Comparison of patients ally, and suggests that the clinical impact of the SE, in terms of radiographic damage, is not that great in carrying a DRB1*04 allele with all patients lacking these alleles revealed a significant difference in Larsen scores.
patients with long-standing disease. The influence of other DRB1 alleles lacking the SE is even less clear. Other studies looking at radiological progression as a measure of disease severity have produced conflicting
Previous studies have considered particular HLA-DRB1 phenotypes to be protective against the development of results, with some reporting an association of DR4 with X-ray changes [25, 26 ] and some not [27, 28] . We disease based on their reduced frequency in RA populations. However, this does not distinguish between protecshould stress that our findings apply only to the more severe RA seen in hospital-based patients attending outtion and non-predisposition. From our study, it appears that HLA-DRB1 types lacking the SE are not equal patient clinics, and cannot necessarily be extrapolated to milder, community-based RA.
with regard to their influence on radiological outcome. Our data suggest that certain HLA-DRB1 alleles (parIn the case of DR1, our study differs from other studies where DR1 was associated with less severe ticularly DRB1*03 and DRB1*13) may provide protection against severe radiological damage, but this effect radiographic changes or more benign disease [26, 29] . We found that the Larsen scores of patients with a is largely lost in the presence of a single SE-carrying allele. Although DRB1*03 and DRB1*13 both appear DRB1*01 phenotype were not significantly different to those with DRB1*04. This was not due to the presence to provide some protection, the effect is most marked in DRB1*13-positive individuals. Radiological severity of an accompanying DRB1*04 allele in many DRB1*01-positive patients since comparison of Larsen in patients with other DRB1 types that have been considered to be protective (DRB1*15, *11/*12 and scores in DRB1*01 groups with or without an accompanying DRB1*04 allele revealed no significant differ-*07) was not statistically different to that in individuals with disease-associated DRB1*01 and *04 types, ence between them (data not shown).
In this study, patients who were homozygous for the although there was an obvious trend towards lower Larsen scores in these groups when unaccompanied by SE demonstrated the highest Larsen scores. Although this was significantly higher than in the SE−/− group, a SE allele. It has been suggested that DRB1 alleles carrying the it was not significantly different to patients carrying a single SE. The highest Larsen score was observed for DERAA sequence prevent the onset of RA [15, 16 ] , although it is clear from our study that individuals DRB1*0401/*0401 homozygotes, which was significantly different to SE−/− cases, although significance carrying these alleles can develop the disease. Interestingly, DRB1*13 alleles which carry the DERAA was lost after correction for multiple testing. Compound SE genotype status (DRB1*0401/*0404 or *0408) was sequence have been associated with reduced severity and/or protection in a number of other diseases, not associated with higher Larsen scores than homozygous SE combinations. 
